Surgeon at the Helm: MAX Surgical Restructures for Aggressive Growth

HACKENSACK, N.J. – July 13, 2026 – In a decisive move to formalize its growth ambitions, MAX Surgical Specialty Management has restructured its C-suite, placing its surgeon-founder, Dr. Jason M. Auerbach, into the Chief Executive Officer role. The leadership shuffle, which also promotes operations head Jeffrey DeBellis to President and COO, is more than a title change; it’s a strategic realignment designed to turbocharge the company’s expansion and solidify its grip on the Northeast’s oral and maxillofacial surgery (OMS) market.

Since its founding in 2022, MAX has pursued an aggressive roll-up strategy, expanding from its New Jersey roots into a five-state network supporting over 50 surgeons in more than 40 locations. This rapid scaling has brought the company to a pivotal juncture, necessitating a leadership structure that can balance clinical integrity with the operational and financial demands of a private equity-backed enterprise. The new appointments aim to do just that, creating clearly defined lanes for clinical vision and operational execution as the company enters its next chapter.

The Architect and the Operator: A Dual-Leadership Model

The restructuring codifies a dual-leadership dynamic that has been implicit in MAX’s success. Dr. Auerbach, a practicing surgeon renowned for his clinical expertise and social media presence as “@bloodytoothguy,” will now formally steer the company’s overall strategy as CEO. His focus remains on what he calls the “clinical and cultural core” of the organization.

"MAX was built on a simple idea: surgeons deserve a partner who understands this specialty from the inside, because we live it every day," Dr. Auerbach stated in the announcement. "This structure lets each of us lead from our strength. I stay closest to the clinical and cultural core of what we're building."

This move keeps the company’s most vital asset—its clinical credibility—at the forefront. It’s a direct message to potential partner practices that the platform is not being run from a distant corporate boardroom but by a peer who understands the day-to-day realities of the operating room. Meanwhile, Jeffrey DeBellis, who previously served as COO, steps into the expanded role of President and COO. With a background in scaling healthcare practices, including co-founding and growing a physical therapy group before its acquisition, DeBellis is the operational architect tasked with running the engine.

"Jason's clinical credibility is the foundation this company is built on, and that hasn't changed," said DeBellis. "What's changed is that we now have the structure to match our ambitions. My focus is making sure every practice that joins MAX gets stronger the day they partner with us, not just on paper, but in the day-to-day realities of running a surgical practice." His domain will be the deep operational infrastructure—from finance and marketing to compliance and recruiting—that allows individual practices to thrive under the MAX umbrella.

The 'Surgeon-Led' Advantage in a Consolidating Market

MAX’s strategic bet is that its “surgeon-led” model is the key differentiator in a crowded field of healthcare consolidation. The oral surgery sector is a hotbed of private equity activity, with platforms like U.S. Oral Surgery Management and Allied OMS also competing to partner with independent practices. In this environment, physician skepticism is high. A 2025 Sermo Barometer survey found that 54% of physicians believe private equity investment decreases the quality of patient care.

MAX’s entire narrative is engineered to counteract this fear. By promising to preserve full clinical autonomy, the company addresses the primary concern of surgeons considering a partnership. The model, common in states with “Corporate Practice of Medicine” (CPOM) laws, separates the clinical practice (owned by licensed physicians) from the management services organization (MSO) that provides business support. MAX’s MSO handles the administrative burdens—billing, HR, IT, marketing—that often bog down practice owners, freeing them to focus on patient care.

The appointment of a surgeon as CEO is the ultimate manifestation of this promise. It signals that clinical priorities will not be subjugated to purely financial ones. This structure is intended to create a partnership of equals, where surgeons gain institutional-grade support without sacrificing the identity and independence of their practices. It’s a compelling proposition for practitioners feeling the squeeze from rising administrative costs and competitive pressures but who are wary of ceding control to faceless investors.

Fueling the Engine: Private Equity's Bet on Specialized Healthcare

Behind MAX’s rapid expansion is a trio of private equity backers: MedEquity Capital, RF Investment Partners, and Kian Capital. Their investment represents a classic “focused roll-up” strategy, concentrating capital and operational expertise within a single, high-margin specialty to achieve regional density and market leadership. The OMS sector, with its complex, non-discretionary procedures, is an attractive target for this playbook.

Investor confidence in the model appears robust. In April 2025, MAX secured a $77 million senior credit facility explicitly to fund its next wave of strategic growth. The backing is not just financial; it’s an endorsement of the company’s surgeon-centric vision. "Our investment in MAX was predicated on our belief in Jason's vision of building the leading surgeon-led oral and maxillofacial surgery platform in the country," said Jeff Ward of MedEquity Capital, a firm with a long history in healthcare services. "We have the utmost faith in Jason's leadership and his team."

This PE backing provides the capital necessary to offer attractive partnership terms, invest in cutting-edge technology, and build out the robust operational support that DeBellis is tasked with overseeing. The synergy is clear: the PE firms provide the fuel, and the new leadership structure is designed to ensure the engine runs efficiently without veering off its clinically-guided course. The long-term play is to create a highly valuable, integrated platform that could eventually be sold to a larger strategic buyer or another private equity firm, delivering significant returns to its investors.

With this leadership realignment, MAX Surgical Specialty Management is doubling down on its founding premise. The company is betting that in the ongoing consolidation of American healthcare, the most successful model will be one that empowers clinicians rather than manages them. By formalizing the roles of its visionary founder and its operational expert, MAX is preparing to prove that a surgeon-led platform can not only maintain its soul but also achieve the scale and dominance its backers demand.